BioSpace News Archive

Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, today announced the dosing of the first patient in a Phase 1 study of AC0176, an orally bioavailable, chimeric degrader molecule designed to target the androgen receptor (AR) with high potency and selectivity.

Two studies provide a radically new picture of how bacterial cells continually repair damaged sections in their DNA.

There have been huge advancements in technology, in the last few years, in terms of providing top-notch diagnostics options for proper management of organ transplants, which in turn has driven the transplant diagnostics market in more than one way.

Vital signs monitoring devices measure the basic functions in humans including pulse rate, body temperature, respiration rate, and blood pressure.

Qpex Biopharma Announces Publication of Data in Nature Communications on the New Synthetic Lipopeptide Antibiotic QPX9003 Targeting Multidrug-Resistant Gram-negative Pathogens.

Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the Shockwave C2 Coronary IVL Catheter received the regulatory approval in Japan.

NAMSA announced today its nearing acquisition of Medanex Clinic , a Belgium-based European preclinical research organization.

RenovoRx, Inc today is reporting its financial results for the year ended December 31, 2021.

ALCEDIAG announces the launch of the EDIT-B Consortium, supported by the European Institute of Innovation and Technology for Health (EIT Health).

Cassava Sciences, Inc. announced that Remi Barbier, its President & CEO, will discuss clinical and corporate updates for Q1 2022 in a fireside chat and presentation on Tuesday, April 5, 2022, at 9am Eastern time.